NEW YORK ( TheStreet) -- CHANGE IN RATINGSAmgen (AMGN - Get Report) was downgraded from Outperform to Market Perform at William Blair. 2013 could be a transitional year for the company.
STOCK COMMENTS / EPS CHANGESAgilent (A) estimates, target boosted at UBS. Shares of A now seen reaching $51, according to UBS. Estimates also upped, as the company can continue to gain market share in the coming quarters. Bristol-Myers Squibb (BMY) target raised at Jefferies. Shares of BMY now seen reaching $41, Jefferies said. A pivotal year for shaping long- term growth. Buy rating. Coventry Health Care (CVH) numbers raised at Jefferies. Shares of CVH now seen reaching $46, Jefferies said. Estimates also raised on appreciation reflected in stock portion of take-out. Hold rating. Eaton Vance (EV) numbers raised at Keefe, Bruyette & Woods. Shares of EV now seen reaching $37, KBW said. Estimates also raised on expectations of positive flows. Market Perform rating. Jarden (JAH) target raised at Oppenheimer. Shares of JAH now seen reaching $68, Oppenheimer said. Re-acceleration in sales should provide momentum. Outperform rating. Lazard (LAZ) numbers raised at Keefe, Bruyette & Woods. Shares of LAZ now seen reaching $37, KBW said. Estimates also raised on strong revenue beat. Market Perform rating. Nielsen Holdings (NLSN) numbers raised at Lazard Capital. Shares of NLSN now seen reaching $40, Lazard said. Estimates also raised on results supportive of capital return potential. Buy rating. Semtech (SMTC) numbers raised at Lazard Capital. Shares of SMTC now seen reaching $39, Lazard said. Estimates also raised on design will pipeline. Buy rating. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.